Wave Life Sciences Slips as Obesity Data Fails to Convince
Wave Life Sciences' shares have fallen nearly 50% after two Wall Street firms cut their price targets due to underwhelming obesity data for the company's candidate WVE-007. The stock is now trading near historic lows, with investors awaiting further data to establish WVE-007 as a standalone obesity therapy.
Wave Life Sciences' stock has plummeted after two Wall Street firms lowered their price targets. The company's obesity candidate, WVE-007, showed a 14.3% reduction in visceral fat in a recent trial. However, this was not enough to convince investors of its potential as a monotherapy. The trial data also preserved lean muscle mass, a differentiated profile compared to other therapies. Despite the setback, Wave Life Sciences has a broader pipeline that may improve sentiment over time. The company plans to initiate a new trial in higher BMI patients with comorbidities in Q2 2026. Wave Life Sciences reported a net loss of $204.4 million in FY 2025, but has cash reserves of $602 million. The next meaningful data inflection will be the Phase 2a initiation in higher BMI patients.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.